Open AccessRoflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1
Author(s) -
Sheng Zhang,
Peng Wu,
JiaBao Liu,
Yingqiang Du,
Zhaohui Yang
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s269029
Subject(s) - doxorubicin , cardiotoxicity , downregulation and upregulation , viability assay , pharmacology , mtt assay , medicine , roflumilast , tumor necrosis factor alpha , cancer research , gene knockdown , senescence , western blot , inflammation , chemistry , cell growth , cell , immunology , apoptosis , chemotherapy , biochemistry , gene , copd
Cardiotoxicity is an important side effect of the treatment of a malignant tumor with Doxorubicin. Currently, decreasing the dosage of Doxorubicin to alleviate the side effects on cardiac function is the common method to deal with the cardiotoxicity induced by Doxorubicin. The present study aims to investigate the therapeutic effects of Roflumilast on Doxorubicin-induced inflammation and cellular senescence, as well as the potential mechanism in H9c2 myocardial cells.